A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHObroad
sbli-ant3310 · Horizon Europe grant · 2023-02-01–2025-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs. The effectiveness of β-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of β-lactamase enzymes by drug-resistant bacteria. We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-in-class serine-β-lactamase inhibitor, intended for the treatment of hospital-acquired infections caused by drug-resistant pathogens. Our treatment has been pre-clinically proven to be efficacious against all three pathogens deemed a critical priority by the World Health Organization (WHO).We will conduct three clinical trials and next out-license ANT3310 to a pharmaceutical partner. We expect market approval by 2029 and that ANT3310 will generate over €10bn in sales within 13 years.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ANTABIO | FR | coordinator | €2,500,000 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.